TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05108571
Drug: DA-5210 10/1000mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose administration (one tablet once a day)
Study: NCT05933499
Drug: IV placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV placebo (administered at 0, 4, 16, 28, and 40 weeks)
Study: NCT05678933
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (750 mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
Study: NCT06350630
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo once daily by oral route (no active drug - same dosage as hydroxychloroquine )
Study: NCT06511349
Drug: YOLT-203
Approvals — FDA: no, EMA: no, PMDA: no
Description: The IP is administered intravenously at the predetermined dose.
Study: NCT05214495
Drug: topical oral Omega-3 hydrogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical oral Omega-3 hydrogel prepared from fish oil
Study: NCT05214495
Drug: conventional preventive treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical treatment including antifungal agents, anti-inflammatory mouthwash, sodium bicarbonate mouthwash.~Topical anesthetics agent, topical analgesic gel as well as systemic analgesics (if needed)
Study: NCT05061732
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5g bid
Study: NCT05061732
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1g bid
Study: NCT05061732
Drug: Tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5g qid
Study: NCT05683340
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, tablet, once daily, for 12 weeks
Study: NCT06359002
Drug: BYON4413
Approvals — FDA: no, EMA: no, PMDA: no
Description: BYON4413 will be administered by IV infusion.
Study: NCT05293249
Drug: Hylenex
Normalized name: Hylenex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hylenex® recombinant will be used for dMAb AZD5396 and dMAb AZD8076 dose preparation at the clinical site.
Study: NCT05931367
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04883931
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml 0.9% normal saline will drop on both eyes twice in a day.
Study: NCT06574555
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The outcome of patient n in each sequence will determine the dose to be allocated patient n+1.~Successive doses will be determined with the up-and-down k-in-row design method for ED90 determination:~* Failure: the dose should be increased in one level (+0.02 µg/kg) after failure to respond (arterial hypotension);~* Success: decrease in one level (-0.02 µg/kg) upon successful response (no arterial hypotension), but only after observing at least k-consecutive positive responses at the same dose (in this case, k=7); otherwise, remain at the same dose.~This will be done until each sequence completes n=30.
Study: NCT06008860
Drug: Experimental: Primary Cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astepro (azelastine) is a second generation antihistamine, as well as an anti-inflammatory and mast cell stabilizer8. It is available as a 0.1% and 0.15% nasal spray by prescription in the USA and over-the-counter in the European Union (EU). Dosing for adults and adolescents 12 years and older is 1 or 2 sprays per nostril twice daily (0.1%) or 2 sprays per nostril once daily (0.15%)9. It is approved by the FDA for treatment of seasonal allergic rhinitis symptoms (rhinorrhea, sneezing, and nasal pruritus) in adults and children 2 years and older, perennial allergic rhinitis in adults and children ages 6 months and older, and the symptoms of vasomotor rhinitis (rhinorrhea, nasal congestion and postnasal drip) in adults and adolescents 12 years and older9.
Study: NCT06143956
Drug: LY3305677
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC. ISA specific interventions will be listed in the ISA.
Study: NCT06143956
Drug: LY3841136
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC. ISA specific interventions will be listed in the ISA.
Study: NCT05624528
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill that contains no medicine
Study: NCT02579187
Drug: Anesthesia
Normalized name: anesthesia tray
Approvals — FDA: no, EMA: no, PMDA: no
Description: all subjects will receive local infiltrative anesthesia, prior to extraction of the tooth
Study: NCT06158516
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle
Study: NCT02579187
Drug: 5µg of pSil-miR200c and 5µg of PMIS miR200a
Normalized name: Betagen brand of Betamethasone and Gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects in the experimental group will receive a 5µg of pSil-miR200c and 5µg of PMIS miR200a plasmids in a biodegradable sponge (type I bovine collagen) to stabilize the clot
Study: NCT06642441
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a standard adjuvant chemotherapy treatment regimen for each adjuvant chemotherapy cycle. The dosage of adjuvant chemotherapy drugs can be customized according to the clinical judgment of the doctor.
Study: NCT05237284
Drug: SAR443820
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet oral
Study: NCT05237284
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT05983445
Drug: genakumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg s.c.
Study: NCT05983445
Drug: placebo for genakumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c.
Study: NCT05983445
Drug: Diprospan
Normalized name: Irospan Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7mg i.m.
Study: NCT05114668
Drug: EVT801
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage 1: Patients will be dosed orally with EVT801 capsules at the dose and schedule to which they are assigned.~Stage 2: Patients will be dosed orally with EVT801 capsules at the MTD / RP2D identified in Stage 1 of the study.
Study: NCT05575180
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo
Study: NCT06650852
Drug: Placebo of BRII-179
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of BRII-179 will be given via intramuscular injection
Study: NCT06650852
Drug: Placebo of BRII-835
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of BRII-835 will be given via subcutaneous injection
Study: NCT05476900
Drug: HR19042 Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR19042 Capsules
Study: NCT05196035
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to finerenone, treatment duration will be 180±7 days
Study: NCT06651476
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo will be administered over 30 minutes by intravenous infusion and repeated 30 minutes after the end of the first infusion.
Study: NCT05053165
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy subjects will be randomized to receive placebo once daily orally
Study: NCT06419374
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT06532630
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be given at a dose of 250 mg/m2/day intravenously (IV) for 3 days prior to anti-CD19-CAR-T cells infusion.
Study: NCT06458010
Drug: YOLT-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: The IP is administered intravenously at the predetermined dose.
Study: NCT05516758
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06772584
Drug: Ginkgobiloba
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group s take it as treatment of deep sleep in nectornal enuresis
Study: NCT05644262
Drug: T2:C100
Approvals — FDA: no, EMA: no, PMDA: no
Description: The active study intervention, T2:C100, is an oral combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) in a digestible oil. T2:C100 is a full spectrum oral solution with five non-reactive ingredients: delta-9-tetrahydrocannabinol (THC), cannabidiol (CBD), a pharmaceutical grade medium chain triglyceride (MCT) oil, and two flavoring agents (lemon and peppermint).~During the double-blind treatment period, participants will receive 1mL study drug (T2:C100) twice daily for Baseline - Day 7 (approximately 1 week), and then will increase to 2mL study drug twice for the remainder of the double-blind treatment period (Day 7 - Week 12 (approximately 11 weeks)).~Participants who enter the Open Label Extension will receive 1mL study drug (T2:C100) twice daily for Week 12 - Week 13 (approximately 1 week), and will then increase to 2mL study drug twice daily for the remainder of the Open Label Extension (Week 13 - Week 26 (approximately 23 weeks)).
Study: NCT05644262
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo in a digestible oil. The placebo contains only three non-reactive ingredients: medium chain triglyceride (MCT) oil and two flavoring agents (lemon and peppermint).~During the double-blind treatment period, participants will receive 1mL placebo twice daily for Baseline - Day 7 (approximately 1 week), and then will increase to 2mL placebo twice for the remainder of the double-blind treatment period (Day 7 - Week 12 (approximately 11 weeks)).
Study: NCT05813288
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of placebo tablet
Study: NCT05637606
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In both the group, the target MAP can be maintained by means of bolus of ephedrine (2.5 mg) or Etilefrine (1 mg). The continuous infusion of norepinephrine, as decided by the attending anesthetist, may be started at any point of the intraoperative period. The starting dose of norepinephrine is the lowest needed to reach the predefined MAP target.
Study: NCT06482892
Drug: TP03HN106
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the dose escalation phase, subjects will undergo a dose escalation trial of intravenous injection of TP03HN106 for 5 consecutive days to evaluate the safety and tolerance of the subjects to the injection dose of TP03HN106. The preset initial dose for this experiment is 10U/kg, with gradient doses of 20, 30, 40, and 50U/kg. Observe the subjects receiving the investigational drug for any adverse events (AEs) after daily intravenous injection.~During the maintenance treatment phase, the subjects will undergo two consecutive treatment courses at the final dose during the dose escalation phase. During each treatment course, subjects will complete the collection of efficacy and safety data for 14 consecutive days of medication (administered every 2 days) and 14 days of discontinuation to evaluate the efficacy and safety of TP03HN106 for subjects with critical limb ischemia.
Study: NCT06200779
Drug: Empirically H. pylori eradication treatment with bismuth quadruple therapy (Pylera®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Described in Arms section
Study: NCT06200779
Drug: PPI, amoxicillin 1 g and clarithromycin 500 mg, twice daily, for 10 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered to patients randomized to Intervention group and with H. pylori clarithromycin-sensitive strain
Study: NCT05280782
Drug: Ga-68 Galmydar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous injection of the PET radiotracer 68Ga-Galmydar.
Study: NCT05062356
Drug: EPINEPHrine 1:200,000 / Prilocaine HCl 4 % 1.8 ML Cartridge
Normalized name: epinephrine 1:200,000 / prilocaine HCl 4 % 1.8 ML Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10cc
Study: NCT05062356
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15mg
Study: NCT05092646
Drug: Drug/Placebo: 0.9% Normal Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug/Placebo: 0.9% Normal Saline
Study: NCT04700826
Drug: Direct Oral Anticoagulants
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: choice of DOAC (apixaban, dabigatran, edoxaban or rivaroxaban) according to local practice
Study: NCT06280690
Drug: SGM-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGM-101 is cea-targeted fluorescent dye
Study: NCT06004128
Drug: VYD222
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody
Study: NCT05797558
Drug: Medical treatment (eplerenone)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial dose of eplerenone is 25 mg twice daily. The dose will be increased by 50 mg every fourth week until systolic blood pressure of 140 mmHg and diastolic blood pressure of 90 mmHg or lower has been reached and biochemical control (plasma renin above the middle of the reference range, i.e \> \~20 mIU/L) is attained and/or hyperkalemia develops. The maximal dose of eplerenone is 300 mg twice daily.
Study: NCT05948475
Drug: Physician's Choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: For subjects receiving FOLFOX or FOLFIRI, the subject will receive treatment every two weeks, with two administrations per each 28-day cycle.
Study: NCT06446245
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: adjunctive doxycycline to standard anti-tuberculous treatment and corticosteroid therapy
Study: NCT06446245
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06446245
Drug: Anti Tuberculosis Drug
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anti-tuberculous therapy
Study: NCT06446245
Drug: Adjunctive corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive corticosteroids to be dosed at 0.4mg/kg/day of dexamethasone or equivalent for week 1, then 0.3mg/kg/day for week 2, 0.2mg/kg/day for week 3, 0.1mg/kg/day for week 4, then tapered to stop over the next 4 weeks. Other forms of corticosteroids are also acceptable eg. hydrocortisone, methylprednisolone at the equivalent dosage
Study: NCT04821648
Drug: RJV001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection in the abdomen
Study: NCT04821648
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo formulation has the same shape, color, and qualitative composition as the RJV001 freeze dried powder, with the exception that RJV001 drug substance has been removed. For each cohort group, a placebo will be injected in a single site in the same area as the treatment.
Study: NCT05602064
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen is a non-steroidal anti-inflammatory drug which acts by reducing the production of cyclo-oxygenases (COX-1 and COX-2)- derived prostanoids in the blood
Study: NCT05427383
Drug: KN026/Placbo Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV KN026/Placebo at 30 mg/kg on D1, Q3W
Study: NCT05927922
Drug: Oral Ibuprofen (Abbott, Egypt)
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen is analegisic drug used to relieve pain
Study: NCT06368167
Drug: SHR2554
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR2554
Study: NCT05082376
Drug: CLM Original
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunscreen lip balm.
Study: NCT05123820
Drug: Treatment period A
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam solution for oral administration. Omeprazole hard capsule for oral administration.
Study: NCT05123820
Drug: Treatment period B
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-1014-6470 soft capsule for oral administration. Midazolam solution for oral administration. Omeprazole hard capsule for oral administration.
Study: NCT05508009
Drug: Cyclophosphamide 1200 mg/Kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 1200 mg/Kg will be administered as part of the conditioning regimen A prior to HSCT
Study: NCT05508009
Drug: Cyclophosphamide 100 mg/Kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 100 mg/Kg will be administered as part of the conditioning regimen B prior to HSCT
Study: NCT05340725
Drug: DEX-IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive iv DEX 1µ/kg diluted in 100 ml saline and given slowly iv infusion over 10 min. 30 min. before induction of anesthesia.
Study: NCT05340725
Drug: DEX-Rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive rectal DEX suppository formulation at approximately 1µ/kg at 30 min. before induction of anesthesia
Study: NCT05340725
Drug: DEX-Nano-Rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive rectal DEX suppository in the Niosomes formulation at approximately 1µ/kg at 30 min. before induction of anesthesia
Study: NCT05269381
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05687890
Drug: Placebo of SC0062
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
Study: NCT05794165
Drug: Thrombate infusion
Normalized name: Thrombate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus intravenous infusion of Thrombate will be given to achieve antithrombin (AT) activity levels at 150% before the 3rd dose of Enoxaparin. The dose will be based on patient weight.
Study: NCT05794165
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline will be given as one time IV before the 3rd dose of Enoxaparin. The dose will be based on patient weight.
Study: NCT05687890
Drug: SC0062 medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
Study: NCT05865743
Drug: SDD
Normalized name: TRACH ANTI-DISCONNECT DEVICE,SHLEY #SSDD
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention group receives SDD treatment additional to standard care, comprising two distinct liquids for oral administration: first the 5 ml amphotericin B suspension (100 mg/ml) and subsequently the 5 ml SDD base for suspension, containing both colistin sulphate (20 mg/ml) and tobramycin sulphate (16 mg/ml).~Patients take the 5 ml amphotericin B, followed by the 5 ml SDD base for suspension, four times daily for one week, starting three days prior to the surgery. On the day of surgery, intake is limited to an early morning and a late evening dose.
Study: NCT05330182
Drug: LMN-201
Normalized name: NUTRITION SUPL TRAUM-AID HBC/LMN PWD
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMN-201 consists of orally delivered whole, dried, non-viable biomass of spirulina (Arthrospira platensis) grown from 4 separate strains, each of which has been engineered to express one of the following therapeutic proteins:~* 3 toxin-binding proteins that bind and inhibit C. difficile toxin B (TcdB), an essential virulence factor for C. difficile~* 1 lysozyme-like enzyme that selectively degrades the cell wall of C. difficile and causes rapid destruction of the organism
Study: NCT06298383
Drug: Diclofenac Potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Non-steroidal anti inflammatory drug. cataflam is known for its potent anti inflammatory and analgesic properties. each patient will receive one tablet of cataflam 50 mg 1 hour before treatment.
Study: NCT06298383
Drug: Prednisolone Oral Tablet
Normalized name: prednisolone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids are potent anti inflammatory drugs, patients are going to receive one tablet of 30 mg solupred one hour before treatment
Study: NCT06236672
Drug: GLP-1 receptor agonist
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 RA initiated between January 2019 and December 2022
Study: NCT02393482
Drug: Estroprogestinic therapy (Etinil-estradiol/levonorgestre)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etinil-estradiol/levonorgestrel (100 mcg/20 mcg)/die
Study: NCT02393482
Drug: Gonadotropin-releasing hormone agonist (Leuprorelin acetate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprorelin acetate (3,75 mg/2 ml)/month
Study: NCT00000941
Drug: Pravastatin sodium
Normalized name: Pravastatin Sodium
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000941
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04665648
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo iv. just before coronary intervention, ivgtt. up to 48h after coronary intervention
Study: NCT05136755
Drug: Placebo Cap
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of placebo as a comparator
Study: NCT06091085
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sugar pills administered for 3 nights, half-dose (1 pill) on the first night followed by full dose (2 pills) for 2 nights
Study: NCT04452851
Drug: COPD Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaler medication to support quick relief from COPD symptoms
Study: NCT05266768
Drug: IBI346
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI346 Antibody and IBI346 CAR-T cell injection
Study: NCT06307925
Drug: HC010
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: HC010 Q2W/28d intravenous infusion
Study: NCT05534321
Drug: Standard of care systemic therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating medical oncologist. Patients may receive systemic therapy concurrently and there are no restrictions on initiation of systemic agents after radiotherapy including immunotherapy and hormonal therapy, the timing of which will be determined by a consensus between the treating medical and radiation oncologists.